Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1365-4632.2009.04395.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessment of information quality in the largest Danish Facebook group on atopic diseases: a mixed bag of help and harm.
Front Allergy
January 2025
Department of Public Health, Environment, Occupation, and Health, Aarhus University, Aarhus, Denmark.
Background: Patient education is an important part of the management of atopic diseases such as allergic rhinitis, atopic dermatitis, and asthma. Given the increasing reliance on social media platforms such as Facebook for health-related discourse, there are concerns about the accuracy and quality of the shared information.
Aim: The aim of this study was to categorize and assess the quality of the information shared within the largest Danish Facebook group focusing on atopic diseases.
Retraction Note: Comment on - Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis.
Neurosurg Rev
January 2025
Lab in Biotechnology and Biosignal Transduction, Department of Orthodontics, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai-77, Tamil Nadu, India.
Retraction Note: Comment on - "Endoscopic treatment of sagittal suture synostosis - a critical analysis of current management strategies".
Neurosurg Rev
January 2025
Lab in Biotechnology and Biosignal Transduction, Department of Orthodontics, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha Dental College and Hospital, Saveetha University, 77, Chennai, Tamil Nadu, India.
Comments on "Effect of colistin combined with sulbactam: 9 g versus 12 g per day on mortality in the treatment of carbapenems resistant Acinetobacter baumannii pneumonia: A randomized controlled trial".
Int J Infect Dis
January 2025
Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan; Oku medical clinic, Shimmori 7-1-4, Asahi-ku, Osaka 535-0022, Japan; Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine, School of Public Health, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan. Electronic address:
From Vision to Reality: The EU's Pharmaceutical Reforms and the Path to Improved Access.
Pharmacoecon Open
January 2025
Department of Health Policy and Medical Technology Research Group, LSE Health, London School of Economics and Political Science, London, UK.
Disparities in access to oncology medicines in European Union (EU) member states can impact patient outcomes profoundly, with availability and timely access varying significantly across and within member states. This paper discusses the intersection of the new European Health Technology Assessment Regulation (HTAR), the provisions of the proposed pharmaceutical legislation and their potential impacts on access to oncology medicines across EU member states. The HTAR, seeking to standardise the clinical evaluation of new medicines, has the potential to streamline the evaluation process but also risks oversimplifying diverse national healthcare needs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!